Business
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming
About this update from Chemocentryx Inc.
[{"type":"text","content":"SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN). 18th European Meeting on Complement in Human Disease (EMCHD) Date: August 26-29, 2022Location: Bern, SwitzerlandPosters: Seven (7) encore posters are planned, highlighting TAVNEOS for the treatment of ANCA-associated vasculitis, and the role of C5a and C5aR in severe HS and LNPoster Availability: August 27, 2022, 7:30 a.m. CEST – August 29, 2022, 2:00 p.m. CEST Rheumatology Advanced Practice Providers (RhAPP) 2022 National Conference Date: September 8-10, 2022Location: Scottsdale, ArizonaPosters: Two (2) encore posters are planned, highlighting TAVNEOS for the treatment of ANCA-associated vasculitis as it relates to health-related quality of life and glucocorticoid toxicityPoster Availability: September 8-10, 2022 Medscape LIVE! 15th Annual Perspectives in Rheumatic Diseases Conference Date: September 8-10, 2022Location: Las Vegas, NevadaPosters: Two (2) encore posters are planned, highlighting TAVNEOS for the treatment of ANCA-associated vasculitis as it relates to health-related quality of life and glucocorticoid toxicityPoster Availability: September 8-10, 2022 INDICATION TAVNEOS® (avacopan) is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Serious hypersensitivity to avacopan or to any of the excipients. WARNINGS AND PRECAUTIONS Hepatotoxicity: Serious cases of hepatic injury have been observed in patients taking TAVNEOS, including life-threatening events. Obtain liver test panel before initiating TAVNEOS, every 4 weeks after start of therapy for six months and as clinically indicated thereafter. Monitor patients closely for hepatic adverse ...